Wet Macular Degeneration
📧 Sign up to get email alerts when something new happens for Wet Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EU authorizes Rimmyrah (ranibizumab) from Qilu Pharma Spain S.L. for indications including wet age-related macular degeneration, macular ede…
-
EMA approval · 2026-08-18EMA Authorised: Vislyfa (ranibizumab) — Lupin Europe GmbH
The EMA has authorised Vislyfa (ranibizumab) by Lupin Europe GmbH for multiple retinal and diabetic eye diseases, expanding access to this a…
-
EMA approval · 2026-08-03EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
EMA authorises Vabysmo (faricimab) for wet macular degeneration, macular edema, and diabetes-related eye complications.
-
EMA approval · 2026-08-03EMA Authorised: Lytenava (bevacizumab) — Outlook Therapeutics NL B. V.
EMA authorised Lytenava (bevacizumab) for wet age-related macular degeneration, marking an approved product from Outlook Therapeutics NL B. …
-
EMA approval · 2026-07-03EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
Aflibercept-based therapy Opuviz has been authorised in the EU for multiple ocular conditions including wet age-related macular degeneration…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-03EMA Authorised: Rexatilux (ranibizumab) — Intas Third Party Sales 2005 S.L.
Authorisation of Rexatilux (ranibizumab) by EMA for wet age-related macular degeneration.
-
EMA approval · 2026-07-01EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) for multiple ophthalmic conditions including wet age-related macular degeneration, macular edema, and…
-
EMA approval · 2026-06-16EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) by Celltrion Healthcare Hungary Kft. for multiple retinal diseases including wet age-related macular …
-
EMA approval · 2024-03-26EMA Authorised: Ximluci (ranibizumab) — STADA Arzneimittel AG
European Medicines Agency authorised Ximluci (ranibizumab) for indications including wet age-related macular degeneration, macular edema, an…